PMA device
NovaSure Impedance Controlled Endometrial Ablation System
Hologic, Inc. · Device, Thermal Ablation, Endometrial (MNB, Class III) · First FDA decision Sep 28, 2001, newest Jan 4, 2022Uterine fibroids and heavy menstrual bleeding
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
16
PMA pathway
Device trials
2
Naming "NovaSure Impedance Controlled"
MAUDE reports
861
Brand "NovaSure Impedance Controlled", since 2015
PubMed studies
9
Mentioning "NovaSure Impedance Controlled"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NovaSure Impedance Controlled Endometrial Ablation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 16 decisions filed under this name.
P010013-S085 · Decided Jan 4, 2022 · 92 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, thermal ablation, endometrial (MNB) · Obstetrics & Gynecology
5 more FDA decisions with a free account
Older decisions: P010013-S058, P010013-S050, P010013-S047, P010013-S022, P010013-S019, P010013-S018, P010013-S011, P010013-S003, P010013-S001, P010013
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "NovaSure Impedance Controlled", any status and sponsor, newest update first.
Aristotle University Of ThessalonikiAcademic, hospital or other
NCT01173965 · 66 participants · Start Jan 2008 · Primary completion Feb 2010
Device: MEA; Novasure · For: Dysfunctional Uterine Bleeding
Sites: Thessaloniki, Greece · 2 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NovaSure Impedance Controlled", and for the whole product code for context.
This brand
861 reports: 50 malfunction, 807 injury, 4 death
Whole product code MNB
2,839 reports: 909 malfunction, 1,913 injury, 13 death
Newest reports for this brand
19446895 · Received Jun 3, 2024 · Event dated Jan 23, 2024
Device type: Device, Thermal Ablation, Endometrial (MNB)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1094-2014 · Started Jan 24, 2014 · Posted by FDA Feb 26, 2014
Reason given: NovaSure Radiofrequency Control Units may not meet a requirement of the electrical standard, IEC 60601-1,
Cause as FDA categorized it: Component design/selection · Device type: Device, Thermal Ablation, Endometrial (MNB)
Published research
The most relevant PubMed records for "NovaSure Impedance Controlled"[tiab]. The summary above synthesizes these.
- NovaSure impedance-controlled system for endometrial ablation.
Gallinat A, Nugent W · J Am Assoc Gynecol Laparosc · 2002Research Support, Non-U.S. Gov't
- NovaSure impedance controlled system for endometrial ablation: the experience of the first UK reference centre.
Elmardi A, Furara S, Khan F, et al. · J Obstet Gynaecol · 2009
- NovaSure impedance controlled endometrial ablation: long-term follow-up results.
Fulop T, Rákóczi I, Barna I · J Minim Invasive Gynecol · 2007Clinical Trial
- NovaSure impedance controlled system for endometrial ablation: three-year follow-up on 107 patients.
Gallinat A · Am J Obstet Gynecol · 2004Evaluation Study
- Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study.
Sabbah R, Desaulniers G · J Minim Invasive Gynecol · 2006Clinical Trial
- Pathology of the NovaSure (radio-frequency) impedance-controlled endometrial ablation system.
Fadare O, Qin L, Martel M, et al. · Arch Pathol Lab Med · 2005Case Reports
- A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia.
Cooper J, Gimpelson R, Laberge P, et al. · J Am Assoc Gynecol Laparosc · 2002Clinical Trial, Comparative Study
- Quality of life should be considered the primary outcome for measuring success of endometrial ablation.
Abbott JA, Hawe J, Garry R · J Am Assoc Gynecol Laparosc · 2003Comparative Study, Research Support, Non-U.S. Gov't
- Assessment and comparison of intraoperative and postoperative pain associated with NovaSure and ThermaChoice endometrial ablation systems.
Laberge PY, Sabbah R, Fortin C, et al. · J Am Assoc Gynecol Laparosc · 2003Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code MNB.
- Genesys HTA SystemAxora Medical, Inc. · PMA 2022
- Minerva Endometrial Ablation SystemAxora Medical, Inc. · PMA 2025
- Mara Water Vapor Ablation SystemCooperSurgical, Inc. · PMA 2023
- Hydro Thermablator Endometrial Ablation SystemAxora Medical, Inc. · PMA 2020
- Cerene® Cryotherapy DeviceChannel Medsystems, Inc. · PMA 2026
- Her Option Cryoablation Therapy SystemCooperSurgical, Inc. · PMA 2011
- Minitouch 3.8 Era System (Minitouch System)Microcube, LLC · PMA 2026
- AEGEA Vapor SystemCooperSurgical, Inc. · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.